These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Gisbert JP; Calvet X Aliment Pharmacol Ther; 2011 Sep; 34(6):604-17. PubMed ID: 21745241 [TBL] [Abstract][Full Text] [Related]
25. Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates. Romano M; Iovene MR; Russo MI; Rocco A; Salerno R; Cozzolino D; Pilloni AP; Tufano MA; Vaira D; Nardone G J Clin Pathol; 2008 Oct; 61(10):1112-5. PubMed ID: 18755715 [TBL] [Abstract][Full Text] [Related]
26. Treatment of Helicobacter pylori infection. Cavallaro LG; Egan B; O'Morain C; Di Mario F Helicobacter; 2006 Oct; 11 Suppl 1():36-9. PubMed ID: 16925610 [TBL] [Abstract][Full Text] [Related]
27. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. Wong WM; Gu Q; Chu KM; Yee YK; Fung FM; Tong TS; Chan AO; Lai KC; Chan CK; Wong BC Aliment Pharmacol Ther; 2006 Feb; 23(3):421-7. PubMed ID: 16423001 [TBL] [Abstract][Full Text] [Related]
28. Antibiotic susceptibility of Helicobacter pylori in central Germany and its relationship with the number of eradication therapies. Selgrad M; Meissle J; Bornschein J; Kandulski A; Langner C; Varbanova M; Wex T; Tammer I; Schlüter D; Malfertheiner P Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1257-60. PubMed ID: 23863261 [TBL] [Abstract][Full Text] [Related]
29. One-week versus two-week H2-receptor antagonist in combination with amoxicillin and tinidazole for eradication of Helicobacter pylori infection. Hsu CC; Chen JJ; Hu TH; Lu SN; Changchien CS Hepatogastroenterology; 2005; 52(65):1617-21. PubMed ID: 16201128 [TBL] [Abstract][Full Text] [Related]
30. Rifabutin-based Fourth and Fifth-line Rescue Therapy in Patients with for Sung J; Kim N; Park YH; Hwang YJ; Kwon S; Na G; Choi JY; Kang JB; Kim HR; Kim JW; Lee DH Korean J Gastroenterol; 2017 Feb; 69(2):109-118. PubMed ID: 28239079 [TBL] [Abstract][Full Text] [Related]
31. Helicobacter pylori resistance rates for levofloxacin, tetracycline and rifabutin among Irish isolates at a reference centre. O'Connor A; Taneike I; Nami A; Fitzgerald N; Ryan B; Breslin N; O'Connor H; McNamara D; Murphy P; O'Morain C Ir J Med Sci; 2013 Dec; 182(4):693-5. PubMed ID: 23625165 [TBL] [Abstract][Full Text] [Related]
34. Current options for the treatment of Helicobacter pylori. Georgopoulos SD; Papastergiou V; Karatapanis S Expert Opin Pharmacother; 2013 Feb; 14(2):211-23. PubMed ID: 23331077 [TBL] [Abstract][Full Text] [Related]
35. Review article: alternative antibacterial agents for Helicobacter pylori eradication. Guslandi M Aliment Pharmacol Ther; 2001 Oct; 15(10):1543-7. PubMed ID: 11563992 [TBL] [Abstract][Full Text] [Related]
36. World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. Suzuki H; Mori H J Gastroenterol; 2018 Mar; 53(3):354-361. PubMed ID: 29138921 [TBL] [Abstract][Full Text] [Related]
37. Evaluating treatments with rifabutin and amoxicillin for eradication of Helicobacter pylori infection in adults: a systematic review. Xirouchakis E; Georgopoulos SD Expert Opin Pharmacother; 2022 Feb; 23(2):201-210. PubMed ID: 34595999 [TBL] [Abstract][Full Text] [Related]
38. Rescue therapy with rifabutin regimen for refractory Helicobacter pylori infection with dual drug-resistant strains. Kuo CJ; Lin CY; Le PH; Chang PY; Lai CH; Lin WR; Chang ML; Hsu JT; Cheng HT; Tseng CN; Lin CJ; Su MY; Hsieh SY; Chiu CT BMC Gastroenterol; 2020 Jul; 20(1):218. PubMed ID: 32650737 [TBL] [Abstract][Full Text] [Related]
39. Rifamycin use for treatment of Boyanova L; Markovska R; Hadzhiyski P; Kandilarov N; Mitov I Future Microbiol; 2020 Aug; 15():1185-1196. PubMed ID: 32954842 [No Abstract] [Full Text] [Related]